Evidence of extensive cellular immune response after SARS-CoV-2 vaccination in ocrelizumab-treated patients with multiple sclerosis

被引：0
|
作者：
Mosche Pompsch
Neslinur Fisenkci
Peter A. Horn
Markus Kraemer
Monika Lindemann
机构：
[1] Alfried Krupp Hospital,Department of Neurology
[2] University of Duisburg-Essen,Institute for Transfusion Medicine, University Hospital Essen
[3] Medical Faculty of Heinrich-Heine-University,Department of Neurology
来源：
Neurological Research and Practice | / 3卷
关键词：
Ocrelizumab; B-cell depleted patients; SARS-CoV2 vaccination; Comirnaty®; T-cell mediated response; Lack of antibody response; Multiple sclerosis; COVID-19;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Effect of SARS-CoV-2 mRNA vaccination in multiple sclerosis patients treated with disease modifying therapies
    Sormani, M. P.
    Inglese, M.
    Schiavetti, I.
    Carmisciano, L.
    Laroni, A.
    Lapucci, C.
    Da Rin, G.
    Serrati, C.
    Gandoglia, I.
    Tassinari, T.
    Perego, G.
    Brichetto, G.
    Gazzola, P.
    Mannironi, A.
    Stromillo, M. L.
    Cordioli, C.
    Landi, D.
    Clerico, M.
    Signoriello, E.
    Frau, J.
    Ferro, M. T.
    Di Sapio, A.
    Pasquali, L.
    Ulivelli, M.
    Marinelli, F.
    Callari, G.
    Iodice, R.
    Liberatore, G.
    Caleri, F.
    Repice, A. M.
    Cordera, S.
    Battaglia, M. A.
    Salvetti, M.
    Franciotta, D.
    Uccelli, A.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 743 - 744
  • [42] Humoral and cellular immune responses to SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
    Konig, M.
    Lorentzen, A.
    Tran, T.
    Schikora-Rustad, S.
    Leiknes, I. J.
    Vaage, E. B.
    Mygland, A.
    Aaberge, I. S.
    Berge, T.
    Skattebol, L.
    Harbo, H. F.
    Andersen, J. T.
    Vaage, J. T.
    Celius, E. G.
    Munthe, L. A.
    Lund-Johansen, F.
    Nygaard, G. O.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 561 - 561
  • [43] Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli et al
    Connolly, Caoilfhionn Marie
    Koenig, Darya
    Ravi, Srekar N.
    Azar, Antoine
    Kant, Sam
    Dalal, Monika
    Duchen, Jessica
    Seo, Philip
    Antiochos, Brendan
    Paik, Julie J.
    Geetha, Duvuru
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (10)
  • [44] Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies
    Seliner, Johann
    Rommer, Paulus S.
    VACCINES, 2021, 9 (02) : 1 - 12
  • [45] Humoral immune response to SARS-CoV-2 third vaccination in patients with multiple sclerosis and healthy controls: A prospective multicenter study
    Krajnc, Nik
    Hegen, Harald
    Traxler, Gerhard
    Leutmezer, Fritz
    Di Pauli, Franziska
    Kornek, Barbara
    Rommer, Paulus
    Zulehner, Gudrun
    Riedl, Katharina
    Duerauer, Sophie
    Bauer, Angelika
    Kratzwald, Sarah
    Klotz, Sigrid
    Winklehner, Michael
    Deisenhammer, Florian
    Guger, Michael
    Hoeftberger, Romana
    Berger, Thomas
    Bsteh, Gabriel
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 65
  • [46] Humoral immune response to SARS-CoV-2 booster vaccination in patients with multiple sclerosis and healthy controls: a prospective multicenter study
    Krajnc, N.
    Hegen, H.
    Traxler, G.
    Leutmezer, F.
    Di Pauli, F.
    Kornek, B.
    Rommer, P.
    Zulehner, G.
    Riedl, K.
    Duerauer, S.
    Bauer, A.
    Kratzwald, S.
    Klotz, S.
    Winklehner, M.
    Deisenhammer, F.
    Guger, M.
    Hoeftberger, R.
    Berger, T.
    Bsteh, G.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 765 - 766
  • [47] Prolonged SARS-CoV-2 Illness in a Patient Receiving Ocrelizumab for Multiple Sclerosis
    Gibson, Elena G.
    Pender, Melissa
    Angerbauer, Michael
    Cook, Craig
    Jones, Barbara
    Spivak, Adam M.
    Spivak, Emily S.
    Swaminathan, Sankar
    OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (07):
  • [48] Humoral response to SARS-CoV-2 mRNA vaccine in patients with multiple sclerosis treated with natalizumab
    Capuano, Rocco
    Donnarumma, Giovanna
    Bisecco, Alvino
    Grimaldi, Elena
    Conte, Miriana
    d'Ambrosio, Alessandro
    Matrone, Federica
    Risi, Mario
    Borgo, Riccardo Maria
    Altieri, Manuela
    Giuliano, Federica
    Coppola, Nicola
    Galdiero, Massimiliano
    Tedeschi, Gioacchino
    Gallo, Antonio
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [49] Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients
    Bajwa, Hamza Mahmood
    Novak, Frederik
    Nilsson, Anna Christine
    Nielsen, Christian
    Holm, Dorte K.
    Ostergaard, Kamilla
    Witt, Agnes Hauschultz
    Byg, Keld-Erik
    Johansen, Isik S.
    Mittl, Kristen
    Rowles, William
    Zamvil, Scott S.
    Bove, Riley
    Sabatino, Joseph J.
    Sejbaek, Tobias
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 60
  • [50] Durability of immune response after SARS-CoV-2 vaccination in patients with chronic liver disease
    Song, Ruixin
    Yang, Chao
    Li, Qianqian
    Wang, Jiayin
    Chen, Jing
    Sun, Kai
    Lv, Hongmin
    Yang, Yankai
    Liang, Jing
    Ye, Qing
    Gao, YanYing
    Li, Jun
    Li, Ying
    Yan, Junqing
    Liu, Ying
    Wang, Tao
    Liu, Changen
    Zhu, Ping
    Wang, Fei
    Yin, Weili
    Xiang, Huiling
    FRONTIERS IN IMMUNOLOGY, 2023, 14
12345